## ACGL: Arch Capital Group Ltd. - XLF: Financial Services

### Executive Summary

No thesis match: MRS_10 0.8% below STRENGTH zone (3.0-6.0%); PEG 2.24 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($90.38)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Sei Investments Co. Boosts Holdings in Arch Capital Group Ltd. $ACGL**
- Source: MarketBeat | 20251211T132546 | Bullish | Relevance: 99%
- Sei Investments Co. significantly increased its stake in Arch Capital Group Ltd. by 12.0% in the second quarter, now holding 1,607,772 shares valued at $146.39 million. Other institutional investors like Norges Bank, GQG Partners LLC, Champlain Investment Partners LLC, Vanguard Group Inc., and Amundi also made substantial changes to their positions. The article also notes recent insider selling by CFO Francois Morin and provides details on Arch Capital Group's stock performance, earnings, and analyst ratings.

**2. Riposte Capital LLC Has $6.83 Million Holdings in Arch Capital Group Ltd. $ACGL**
- Source: MarketBeat | 20251210T130723 | Somewhat-Bullish | Relevance: 99%
-  Riposte Capital LLC significantly reduced its stake in Arch Capital Group Ltd. (NASDAQ:ACGL) by 40% in Q2, now holding 75,000 shares valued at $6.83 million. Despite this, Arch Capital reported strong quarterly earnings, beating analyst estimates with an EPS of $2.77 and revenue of $5.11 billion. Institutional ownership remains high at 89%, while analysts maintain a consensus "Hold" rating with a target price of $106.85.

**3. Does Arch Capital Still Offer Value After Specialty Insurance Expansion and Strong Long Term Gains?**
- Source: Simply Wall Street | 20251210T144549 | Bullish | Relevance: 99%
- Arch Capital Group (ACGL) is being assessed for its current valuation after significant long-term gains, with recent expansion into specialty insurance and reinsurance. Despite modest short-term returns, the company shows strong long-term performance and is considered undervalued by two different valuation approaches: Excess Returns Analysis and Price vs. Earnings, suggesting potential for continued value. The article encourages investors to use "Narratives" for personalized valuation based on their own assumptions.

**4. Wall Street Has a Mixed Opinion on Arch Capital (ACGL), Here's Why**
- Source: Finviz | 20251209T170750 | Neutral | Relevance: 98%
- Wall Street analysts have a mixed opinion on Arch Capital (ACGL) despite recent price target adjustments. Harry Fong of Roth MKM lowered his price target to $110 while reiterating a Buy rating, citing mixed Q3 2025 earnings where revenue missed expectations but EPS topped forecasts. Conversely, Rowland Mayor of RBC Capital initiated coverage with a Buy rating and a $108 price target, acknowledging a potential top-line slowdown but anticipating strong underwriting margins and growing net investment income to offset it.

**5. First Trust Advisors LP Sells 184,847 Shares of Arch Capital Group Ltd. $ACGL**
- Source: MarketBeat | 20251209T093316 | Somewhat-Bullish | Relevance: 98%
-  First Trust Advisors LP reduced its stake in Arch Capital Group Ltd. (NASDAQ:ACGL) by 24.9% during the second quarter, selling 184,847 shares. Following the transaction, the firm now owns 556,501 shares of the insurance provider, valued at approximately $50.67 million. Several other institutional investors have adjusted their holdings in ACGL, and company CFO Francois Morin also sold 8,000 shares in late November.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Roth Capital | $110 | $125 | -12% |
| 2025-11-17 | Morgan Stanley | $110 | $105 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Roth Capital | main | Buy |
| 2025-11-17 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($1.62M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Vanguard Group Inc: 11.7% (-0.2%)
- Blackrock Inc.: 8.9% (-1.4%)
- Artisan Partners Lim: 6.5% (-0.8%)
- BAMCO Inc.: 5.2% (-4.9%)
- State Street Corpora: 4.6% (-1.0%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.7% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.24 elevated, pricing in significant growth expectations. Forward P/E 10.1x stretched relative to 1% growth. Quality metrics strong (margin 21%). Balance sheet: strong liquidity (7513000000.0x), $2.2B free cash flow. Insider selling cluster ($1.6M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $34.9B |
| Beta | 0.45 |
| 52W Range | $82.45 - $97.40 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.24 |
| Forward P/E | 10.1 |
| Current P/E | 10.2 |
| YoY Growth | 0.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -2.9% to 0.8% (+3.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.2pp (needs >3.0% for momentum thesis). MRS_5 at 1.8% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.82% (CS: 46) | Neutral |
| RSI_14 | 60.6 | Neutral |
| MACD Histogram | -0.14 | Bearish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 1.037x | Above |
| vs SMA200 | 1.029x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $93.64
- **Stop Loss:** $90.38 (3.5% risk)
- **Target:** $96.90 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 423
- **Position Value:** $39,609.72
- **Portfolio %:** 39.61%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-10 (Est: $2.33)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.25 | $2.77 | +22.9% |
| 2025Q2 | $2.30 | $2.58 | +12.2% |
| 2025Q1 | $1.31 | $1.54 | +17.2% |
| 2024Q4 | $1.80 | $2.26 | +25.5% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*